Press Releases
Alm. Brand A/S share buy-back program
Transactions during 03 June 2024 – 07 June 2024On 5 December 2023, Alm. Brand A/S announced a share buy-back program of up to DKK 250 million, as described in company announcement no. 23/2023. On 8 February 2024, Alm. Brand A/S announced an increase of the existing share buy-back programme by DKK 100 million to DKK 350 million and extension of the period for the programme until and including 30 September 2024, as described in... (continue reading...)
Global rankings and trends from the world's most comprehensive, quality-controlled dataset
SAN FRANCISCO, CA / ACCESSWIRE / June 10, 2024 / The 2024 Global Startup Ecosystem Report (GSER) by Startup Genome and the Global Entrepreneurship Network launched today at London Tech Week, in collaboration with the Founders Forum, Informa Tech and London & Partners. The GSER analyzes data from over 4.5 million companies across 300+ entrepreneurial innovation ecosystems and... (continue reading...)
DUBAI, UAE, June 10, 2024 /PRNewswire/ -- XRP Healthcare, a trailblazer in the healthcare sector, is proud to announce the appointment of Mergers and Acquisitions specialist Whitney Lynn as its new Chairman.
This strategic move comes as XRP Healthcare is set to embark on an ambitious mergers and acquisitions (M&A) venture, having successfully registered... (continue reading...)
- SST2 antagonist, 225Ac-SSO110 (satoreotide), is multiple times more potent than SST2 agonist, 225Ac-DOTATATE
- Satoreotide demonstrated durable complete response in standard murine xenograft models of Small Cell Lung Cancer in animal models, versus tumor growth delay with 225Ac-DOTATATE
BERLIN, June 10, 2024 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain... (continue reading...)
- Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases
- Poster to be presented on Commit's Bispecific Complement Engaging (BiCE™) platform
AARHUS, Denmark, June 10, 2024 /PRNewswire/ -- Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces it will present a poster containing key data on its... (continue reading...)
More Press Releases
View Older Stories-
50-State Data: Pandemic Learning Loss, Failure to Equip Children for School Threatens U.S. Economy, Young People’s Future
-
India Breakthrough: Bio Regenerative Precision Medicine Seminar Held in Hyderabad
-
Slate Asset Management Acquires the World Seafood Center in Oslo for Approximately NOK 1.3 Billion
-
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
-
Indonesia's Intellectual Property Office Wins Award in Fight Against Piracy at Interpol Conference
-
Flash News: OKX Wallet Now Supports Full Force
-
RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon
-
Flamingo Therapeutics Announces Poster Presentation at EACR 2024 Congress on FLM-7523 (FTX-001), a First-in-Class Inhibitor of the Long Non-Coding RNA MALAT1
-
Dstny honored with 'Employee Wellbeing Award'
-
Entrust Enables Governments to Transform Citizen Interactions with Digital Identities
-
Best’s Market Segment Report: AM Best Revises Outlook for Global Reinsurance Industry to Positive
-
MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence
-
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
-
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
-
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
-
Share buy-back programme - week 23
-
Anmodning om suspension i enkelte afdelinger under Investeringsforeningen Danske Invest
-
Enduring role of 'treasuring the past' hailed
-
Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
-
Virginie Leroy joins VINCI’s Executive Committee
-
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
-
Preliminary data on early redemptions (prepayments)
-
The sales of VILVI GROUP May 2024
-
Share repurchase programme
-
Quantexa Debuts Q Assist, New Context Aware Generative AI Technology Suite
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 10
-
-
The ECB has issued permission for Laura Križinauskienė to start taking the position of a member of the Management Board of Šiaulių Bankas
-
PowerUP Asia 2024 Opens Tomorrow
-
Exor Press Release - Periodic Report on the Buyback Program
-
FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm²
-
Blueshift Named Market Leader in Research In Action's 2024 Vendor Selection Matrix™ Report for Customer Data Management
-
Mkango Resources Limited Announces Hypromag to Collaborate with Envipro
-
Noble Corporation plc announces agreement to acquire Diamond Offshore Drilling, Inc.
-
Milliman Opens Modelling Excellence Center in Madrid
-
Medincell Publishes Its Consolidated Annual Financial Results
-
Regenx Rights Offering Fully Subscribed
-
Rockit™ Apple fired up to Ready. Set. Rockit. into record season
-
Distributor Orders Nexstim NBS System 5 for European Hospital
-
Subsea7 share repurchases
-
Shell plc First Quarter 2024 Euro and GBP Equivalent Dividend Payments
-
-
Transaction in Own Shares
-
Fingerprint Cards AB (publ) will present at Aktiedagarna in Stockholm on June 12, 2024
-
J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study
-
Mini Harambe uses a Revolutionary Force for Wildlife and Rainforest Conservation
-
Neorejuvenation Explores University Collaborations to Study Belief Change and Neuroplasticity
-
4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)